Adicet Bio to Present at Upcoming Investor Conferences

Rhea-AI Summary

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology firm specializing in allogeneic gamma delta CAR T cell therapies for cancer, announced participation in two upcoming investor conferences. The H.C. Wainwright 24th Annual Global Investment Conference will occur from September 12-14, 2022, with an on-demand presentation by Chen Schor, CEO, available from 7:00 A.M. ET on September 12. Additionally, a corporate overview will be presented at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 8:00 A.M. ET. Live webcasts will be accessible on the company’s website.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in September.

Details of the events are as follows:

H.C. Wainwright 24^th Annual Global Investment Conference, September 12-14, 2022, New York, New York

• An on-demand presentation given by Chen Schor, President & CEO will be available beginning Monday, September 12, 2022 at 7:00 A.M. ET

Jefferies Cell and Genetic Medicine Summit, September 29-30, 2022, New York, New York

• Chen Schor, President & CEO, will present a corporate overview on Friday, September 30, 2022, at 8:00 A.M. ET.

The live audio webcast of the presentations can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907006190/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

What are the upcoming investor conferences for Adicet Bio (ACET) in September 2022?

Adicet Bio will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14 and the Jefferies Cell and Genetic Medicine Summit on September 29-30, 2022.

When will Chen Schor present at the H.C. Wainwright conference for Adicet Bio (ACET)?

Chen Schor, CEO of Adicet Bio, will have an on-demand presentation available starting at 7:00 A.M. ET on September 12, 2022.

What will be presented at the Jefferies Summit for Adicet Bio (ACET)?

At the Jefferies Cell and Genetic Medicine Summit, Chen Schor will present a corporate overview on September 30, 2022, at 8:00 A.M. ET.

Where can I access the live webcasts for Adicet Bio's investor conferences?

Live audio webcasts for Adicet Bio's investor presentations can be accessed on the Investors section of their website.